Entecaver adding 18a-glycyrrhizin to reverse the cirrhosis in the chronic hepatitis patient

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-16009493

Enrollment

Unknown

Registered

2016-10-19

Start date

2017-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B

Interventions

1:enticavir

2:18a-glycyrrhizin

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: The value of FibroScan>9Kpa (ALT is normal) or >9.4Kpa (ALT is abnormal).

Exclusion criteria

Exclusion criteria: combined other hepatitis patients

Design outcomes

Primary

Measure	Time frame
the value of Fibroscan;	—

Countries

China

Contacts

Public ContactChenliang

Shanghai Public Clinical Center

chenliang@shaphc.org+86 18930810000

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026